Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
Open Access
- 15 February 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (4) , 1032-1040
- https://doi.org/10.1158/1078-0432.ccr-07-2056
Abstract
Purpose: CD4+CD25highFoxP3+ regulatory T cells (Treg) have been shown to inhibit the activation and function of T cells that participate in antigen-specific immune responses. Higher levels of Tregs have been reported in the peripheral blood of patients with several types of tumors. In this study, we investigated the number and functionality of CD4+CD25highFoxP3+ Tregs in patients with prostate cancer (PCa), and their potential role in inhibiting antitumor immune responses.Keywords
This publication has 47 references indexed in Scilit:
- Cancer Vaccines: Moving Beyond Current ParadigmsClinical Cancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Regulatory T cells in cancerBlood, 2006
- Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemiaLeukemia, 2005
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cellsBlood, 2004
- Natural versus adaptive regulatory T cellsNature Reviews Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003